CCTG HN11 SELECT has now opened to accrual across Canada and sites in the US. The trial is a randomized, controlled, phase III clinical trial for patients with lateralized oropharyngeal carcinoma (OPC)
MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Muscosal Melanoma
The recently launched Centre for Health Innovation, aims to connect researchers from across multiple disciplines to tackle the most pressing human health challenges. A critical part of the centre will be a new home for the CCTG Tumour Tissue Data Repository and includes a large-scale expansion of its histopathology and biobanking resources.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)
During the holiday season the CCTG central offices will operate with limited coverage and there are key delivery dates for specimen shipments to keep in mind. Normal hours of operation and coverage will resume on Tuesday January 3, 2022.
The CCTG BLC5 MAIN-CAV international trial is now open in Canada testing the addition of a targeted anti-cancer drug to the usual immunotherapy treatment, in patients with metastatic urothelial cancer (mUC).
Three CCTG trials were recently awarded nearly $7.5M from the Canadian Institutes of Health Research (CIHR) 2022 Spring Project Grant competition.
It was recently announced that ExCELLirate Canada has successfully been granted a Research Infrastructure award of $4,159,049 by the Ontario Research Fund for the Innovation Fund Project Grant "ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation".
CCTG trials that were featured at the American Society of Clinical Oncology General Meeting 2022 June 3-7, 2022 – McCormick Place, Chicago
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)
PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)
Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC
Late Recurrence Substudy of A Phase III Randomized Trial of Metformin vs Placebo on Recurrence and Surivival in Early-Stage Breast Cancer
De-escalation of Chemo in HER-2+, ER-, Node-negative, breast cancer patients who achieved complete response after chemo and Dual HER-2 blOckade (DECRESCENDO)
Adjuvant Treatment Guided by Response Post Neoadjuvant Therapy for Stage III Melanoma
NET RETREAT: 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET
Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy
Androgen Suppression combined with Elective Nodal and a Dose Escalated Boost. Stereotactic Body Radiation Therapy vs Brachytherapy Boost (ASCENDE-SBRT)
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes
The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS
STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study
Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.
CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.
“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
Endocrine-Related Cancer 29: 335 - 344, 2022Kulke MH;Ou FS;Niedzwiecki D;Huebner L;Kunz P;Kennecke HF;Wolin EM;Chan JA;O'Reilly EM;Meyerhardt JA;Venook A;
Cancers 14: 2985, 2022Manji A;Samson Y;Deyell RJ;Johnston DL;Lewis VA;Zorzi AP;Berman JN;Brodeur-Robb K;Morrison E;Kee L;Kumar S;Baruchel S;Whitlock JA;Morgenstern DA;
Statist Med 41: 4781 - 4790, 2022Thiessen DL;Zhao Y;Tu D;
Can J Statistics , 2022Ge X;Peng Y;Tu D;
, 2022Allaf M;Kim SE;Harshman LC;McDermott DF;Master VA;Signoretti S;Cole S;Moon H;Adra N;Singer EA;Gills J;Choueiri TK;Leibovich B;Michaelson MD;Shuch B;Lara PN;Heng DYC;Kapoor A;Carducci MA;Haas NB;
JAMA Oncology , 2022Conroy T;Castan F;Lopez A;Turpin A;Ben Abdelghani M;Wei AC;Mitry E;Biagi JJ;Evesque L;Artru P;Lecomte T;Assenat E;Bauguion L;Ychou M;Bouche O;Monard L;Lambert A;Hammel P;Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group;
J Clin Oncol : JCO, 2022Kennecke HF;O'Callaghan CJ;Loree JM;Moloo H;Auer R;Jonker DJ;Raval M;Musselman R;Ma G;Caycedo-Marulanda A;Simianu VV;Patel S;Pitre LD;Helewa R;Gordon VL;Neumann K;Nimeiri H;Sherry M;Tu D;Brown CJ;
